A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease

PURPOSE: To compare the efficacy, safety, and tolerability of waterfree cyclosporine formulation (CyclASol) at 2 concentrations (0.1% and 0.05% of cyclosporine [CsA]) to vehicle when applied twice daily for 16 weeks in patients with dry eye disease (DED). An open-label Restasis (Allergan, Irvine, CA...

Descripción completa

Detalles Bibliográficos
Autores principales: Wirta, David L., Torkildsen, Gail L., Moreira, Helen R., Lonsdale, John D., Ciolino, Joseph B., Jentsch, Garrit, Beckert, Michael, Ousler, George W., Steven, Philipp, Krösser, Sonja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554539/
https://www.ncbi.nlm.nih.gov/pubmed/30703441
http://dx.doi.org/10.1016/j.ophtha.2019.01.024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554539/
https://www.ncbi.nlm.nih.gov/pubmed/30703441
http://dx.doi.org/10.1016/j.ophtha.2019.01.024

Ejemplares similares